Vol.

No.

March 10, 2023Mar 10, 2023

DOWNLOAD THE PDF

UNM’s Sanchez: To provide cancer care to Native American, Hispanic communities, you must first establish trust

Cover Story

Conversation with The Cancer Letter

UNM’s Sanchez: To provide cancer care to Native American, Hispanic communities, you must first establish trust

By Paul Goldberg

No Hispanic woman has ever served as director of an NCI-designated cancer center. This changed a month ago, on Feb. 6, when Yolanda Sanchez became director and CEO of The University of New Mexico Comprehensive Cancer Center.

Regulatory News

Improving on R-CHOP, ODAC votes 11:2 to move Genentech’s Polivy to the first line in diffuse large B-cell lymphoma

By Jacquelyn Cobb

White House

Biden requests $503M increase for NCI, new funds for the Moonshot, $1B for ARPA-H in FY24

By Matthew Bin Han Ong

Free In the Archives

Cancer History Project Panel: How Betty Ford’s and Nancy Reagan’s breast cancer diagnoses changed attitudes to cancer

By Alexandria Carolan

In Brief

Raphael Pollock and George Weiner do a “flip-flop,” replacing each other at Big Ten Cancer Research Consortium, ORIEN

Cleveland Clinic opens cancer center in Abu Dhabi

Rangaswamy Govindarajan named chief of UAMS Hematology and Oncology Division

MD Anderson, Hospital Alejandro Otero Lopez-Manati Medical Center receive DeWitt C. Baldwin, Jr. Award

Funding Opportunities

Cancer Grand Challenges announces global research funding opportunity with nine new challenges

DoD Bone Marrow Failure Research Program anticipated funding opportunities for FY23

DoD Prostate Cancer Research Program anticipated funding opportunities for FY23

DoD Melanoma Research Program anticipated funding opportunities for FY23

Clinical Roundup

NEJM publishes phase III study of nirogacestat in adults with progressing desmoid tumors

SWOG study shows neoadjuvant Keytruda helps prevent recurrence in high-risk melanoma

Tagrisso demonstrated OS benefit in the ADAURA phase III trial for adjuvant treatment of early-stage EGFR-mutated lung cancer

Imfinzi significantly improved EFS in AEGEAN phase III trial for patients with resectable NSCLC

Study reveals how androgen therapy affects breast tissue

NCI Center for Cancer Research study identifies ecDNA as driver of SCLC

Fewer than 1% of telehealth visits are for oncology care

UT Southwestern study suggests cell membrane ‘blebs’ could hold targets for anti-cancer drugs

UT Southwestern study finds response to hormone therapy predicts radiation resistance in ER+ breast cancer

Cancer stage and receptor status indicate risk of breast cancer recurrence

Community engagement can help improve clinical trial diversity

Drugs & Targets

FDA broadens indication for Verzenio in HR+, HER2-, node-positive, high-risk early breast cancer

FDA approves label expansion for VENTANA PD-L1 assay to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo

FDA approves Udenyca autoinjector

FDA updates mammography regulations to require reporting of breast density information and enhance facility oversight

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 45 - December 12, 2025